New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

28 June 2016 - AstraZeneca today announced that the European Commission has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.

The approval includes intravenous use of Zavicefta for the treatment of adult patients suffering from complicated intra-abdominal infections (cIAI); Complicated urinary tract infections, including pyelonephritis; hospital-acquired pneumonia, including ventilator associated pneumonia; and, the treatment of aerobic Gram-negative infections in adult patients who have limited treatment options.

Zavicefta has been developed in response to the urgent need for new antibiotics to treat serious infections that are becoming increasingly resistant, such as multi-drug resistant P. aeruginosa, carbapenem-resistant Gram-negative pathogens, and ESBL-producing Enterobacteriaceae.

View AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder